EDITORIAL DISCLAIMER: The following article is published for educational purposes only. Springfield Physical Therapy & Wellness does not prescribe, dispense, sell, or administer peptide therapies. This content is not medical advice. Peptide therapies are complex, rapidly evolving, and subject to federal and state regulation. Always consult a licensed physician or qualified healthcare provider before considering any peptide-based intervention.
Introduction
In the past several years, GLP-1 receptor agonists have emerged as arguably the most significant pharmaceutical development in metabolic medicine since the discovery of insulin. Medications like semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) have transformed clinical practice and generated both genuine scientific excitement and a considerable amount of cultural noise.
Understanding what these medications are, how they work, what the evidence actually demonstrates, and the important nuances that often get lost in popular coverage is valuable for anyone interested in metabolic health — regardless of whether GLP-1 therapy is appropriate for them personally.
What Is GLP-1?
GLP-1 stands for glucagon-like peptide-1 — a naturally occurring incretin hormone produced by L-cells in the small intestine and colon. It is released in response to food intake and plays several important roles in metabolic regulation:
- Stimulates insulin secretion from the pancreatic beta cells in a glucose-dependent manner (meaning it only triggers insulin release when blood sugar is elevated — reducing hypoglycemia risk)
- Suppresses glucagon release — the hormone that raises blood sugar — thereby reducing hepatic glucose production
- Slows gastric emptying, which reduces the rate at which glucose enters the bloodstream after eating
- Acts on receptors in the brain, particularly the hypothalamus and brainstem, to reduce appetite and increase satiety
- Has direct effects on the cardiovascular system, including anti-inflammatory and cardioprotective properties that have been demonstrated in clinical trials
The multi-mechanism nature of GLP-1 action — affecting blood sugar, appetite, gastric motility, and cardiovascular health simultaneously — is a key reason why GLP-1 agonists have shown such broad clinical utility.
Natural GLP-1 vs. GLP-1 Receptor Agonists
The naturally occurring GLP-1 hormone has a very short half-life — approximately 1–2 minutes — because it is rapidly broken down by an enzyme called DPP-4 (dipeptidyl peptidase-4). This limits its clinical utility as a standalone therapeutic agent.
GLP-1 receptor agonists are synthetic peptide molecules engineered to bind to and activate the GLP-1 receptor while being resistant to DPP-4 degradation. This structural modification dramatically extends their half-life, from minutes to hours or even weeks depending on the specific compound:
| Property | Detail |
| Exenatide (Byetta) | Short-acting; twice-daily injection; first GLP-1 agonist approved by FDA (2005) |
| Liraglutide (Victoza/Saxenda) | Once-daily injection; approved for T2 diabetes and obesity |
| Semaglutide (Ozempic/Wegovy) | Once-weekly injection; approved for T2 diabetes and chronic weight management |
| Tirzepatide (Mounjaro/Zepbound) | Dual GIP/GLP-1 agonist; once-weekly injection; approved for T2 diabetes and obesity |
| Oral semaglutide (Rybelsus) | Once-daily oral tablet; first oral GLP-1 agonist approved by FDA |
The Evidence: What the Clinical Trials Show
The evidence base for FDA-approved GLP-1 receptor agonists is among the strongest in modern pharmacology — built on large, rigorous, randomized controlled trials involving tens of thousands of patients.
Key findings from landmark trials include:
- SUSTAIN and STEP trials for semaglutide: participants with obesity achieved average body weight reductions of 10–15% over 68 weeks — results significantly exceeding prior pharmacological options for weight management
- SURMOUNT trials for tirzepatide: even more substantial weight reductions of 15–21% in trials, approaching outcomes previously associated only with bariatric surgery
- LEADER trial for liraglutide and SUSTAIN-6 for semaglutide: demonstrated statistically significant reductions in major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — in high-risk patients with T2 diabetes
- SELECT trial for semaglutide: demonstrated 20% reduction in MACE in patients with obesity and established cardiovascular disease but without diabetes — a landmark finding
The cardiovascular outcome data for GLP-1 agonists is particularly significant because it demonstrates benefits beyond blood sugar control and weight reduction — suggesting direct cardioprotective mechanisms.
How GLP-1 Agonists Reduce Appetite and Body Weight
The weight-loss mechanism of GLP-1 agonists is an area of active and fascinating research. The primary driver is not simply slowed gastric emptying — it is centrally mediated appetite suppression.
GLP-1 receptors are expressed in multiple brain regions involved in food intake regulation, including the hypothalamus, brainstem nucleus tractus solitarius, and reward pathways. Activation of these receptors reduces hunger signals, increases satiety perception, and — importantly — appears to reduce the hedonic (pleasure-driven) aspects of eating that make dietary restriction so difficult for many people.
Research has also shown effects on ‘food noise’ — the persistent preoccupation with food that many patients with obesity report — with many patients on GLP-1 agonists describing a significant reduction in this cognitive burden.
Compounded GLP-1s: An Important Distinction
During periods when brand-name semaglutide and tirzepatide were on FDA shortage lists, compounding pharmacies were legally permitted to produce compounded versions at significantly lower cost. This provided broader access for many patients who could not afford the $900–1,300 monthly cost of brand-name medications.
However, the FDA removed semaglutide from the shortage list in early 2025 and tirzepatide in late 2024. With the resolution of those shortages, the legal basis for compounding these specific medications was eliminated, and compounding was required to cease after grace periods.
As of the writing of this article, compounded semaglutide and tirzepatide are no longer legally available from 503A compounding pharmacies under the shortage exemption. Anyone currently receiving compounded versions should consult their prescribing physician about transitioning to FDA-approved formulations. The regulatory situation in this area has changed repeatedly and may continue to evolve.
Who Are GLP-1 Agonists Appropriate For?
FDA-approved GLP-1 receptor agonists are currently indicated for:
- Adults with type 2 diabetes mellitus (various agents)
- Adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease
- Adults with established cardiovascular disease and obesity (semaglutide — based on SELECT trial data)
They are prescription medications requiring physician oversight, monitoring for side effects, and individualized clinical assessment. They are not appropriate for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Common Side Effects and Considerations
The most frequently reported side effects in clinical trials are gastrointestinal and include:
- Nausea — most common, particularly during dose escalation; typically improves over weeks
- Vomiting and diarrhea
- Constipation
- Gastroparesis-like symptoms in some patients
More serious but less common concerns that continue to be studied include: pancreatitis risk, gallbladder disease, the theoretical thyroid C-cell tumor risk (from rodent studies; human significance remains unclear), and muscle mass loss alongside fat loss — which has led to increasing interest in combining GLP-1 therapy with resistance training and adequate protein intake.
The Physical Therapy Connection
This is where our perspective as a physical therapy and wellness clinic becomes relevant. As GLP-1 therapy becomes more widespread, physical therapists are increasingly seeing patients who are losing significant weight through these medications and who need structured support to:
- Preserve and build muscle mass during weight loss — resistance training is essential and increasingly recommended alongside GLP-1 therapy
- Address joint pain and mobility limitations that improved with weight loss
- Rebuild physical function and fitness capacity after periods of reduced activity
- Manage musculoskeletal side effects that can accompany rapid body composition changes
If you are taking a GLP-1 medication and want to maximize your results through structured physical therapy and exercise guidance, our team at Springfield PTW can help support that journey.
This article is for educational purposes only. Springfield Physical Therapy & Wellness does not prescribe or administer GLP-1 medications. Consult a licensed physician or endocrinologist for medical decisions regarding GLP-1 therapy.
